Fragment 176-191 is a synthetic peptide derived from the C-terminal portion of human growth hormone (HGH). It is designed specifically to promote fat loss without significantly affecting muscle growth or blood sugar levels. This fragment works by increasing lipolysis (fat breakdown) and reducing lipogenesis (fat storage). Unlike full HGH, it has minimal impact on IGF-1 production. Fragment 176-191 is typically administered by subcutaneous injection, often daily. It is mainly used in research and body-recomposition communities. The peptide is not approved for medical use, and long-term safety data in humans are limited.
Dosing Fragment 176-191
fragment 176-191, It must first be reconstituted with bacteriostatic water, at which point it is typically injected subcutaneously. For fat loss, fragment 176-191 is typically administered at the dosage of 200-500 mcg per day. The full dose may be delivered once in the AM, or it may spread across two doses—one in the morning and another at night, in both cases on an empty stomach. Fragment 176-191 is typically administered over the course of about four weeks.